Mixed COVID vaccine schedules offer stronger boost after Sinovac regimen



© Reuters. FILE PHOTO: Vials of Chinese Sinovac’s CoronaVac vaccine against coronavirus disease (COVID-19) pictured inside the newly inaugurated production lab designated to manufacture the vaccine, in Constantine, Algeria September 29, 2021. REUTERS/Ramzi Boudina

(Reuters) – Giving COVID-19 vaccines from either AstraZeneca-Oxford, Pfizer-BioNTech or Johnson & Johnson (NYSE:) as a booster after two doses of the COVID-19 inactivated-virus vaccine from Sinovac, leads to significantly higher antibodies, a study has found.

The best response was seen when an RNA vaccine was given as a booster after the standard schedule of Sinovac’s CoronaVac, researchers from Oxford University said on Monday, adding that the responses were seen against the Delta and Omicron coronavirus variants too.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



Source link